Related references
Note: Only part of the references are listed.
Letter
Critical Care Medicine
Chris Ka Pun Mok et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
(2022)
Article
Medicine, General & Internal
Sue Ann Costa Clemens et al.
Summary: A study was conducted to evaluate the safety and immunogenicity of a third dose of heterologous or homologous vaccines in Brazilian adults who had previously received two doses of CoronaVac. The results showed that a third dose of heterologous vaccines (recombinant adenoviral vectored vaccine or mRNA vaccine) significantly increased immune responses and could improve protection against infection.
Article
Medicine, General & Internal
Arabella S. Stuart et al.
Summary: The study investigated the mixed use of different COVID-19 vaccines within the same schedule, showing that in certain conditions, heterologous vaccination can achieve similar immunogenicity to homologous vaccination, facilitating rapid global vaccine deployment.
Article
Multidisciplinary Sciences
Raquel Viana et al.
Summary: The SARS-CoV-2 epidemic in southern Africa has experienced three distinct waves, driven by different variants. The recently identified Omicron variant has rapidly spread in South Africa and to numerous countries, raising global concern.
Article
Biochemistry & Molecular Biology
Jingxin Li et al.
Summary: The study suggests that additional COVID-19 vaccine doses may be needed for individuals who initially received CoronaVac. Heterologous boosting with Convidecia, a recombinant adenovirus type 5 (AD5)-vectored vaccine, was found to be safe and more immunogenic than homologous boosting with CoronaVac in adults previously vaccinated with CoronaVac.
Article
Medicine, General & Internal
Roos S. G. Sablerolles et al.
Summary: This study investigated the immunogenicity and reactogenicity of a homologous or heterologous booster in healthcare workers who had received a single-shot Ad26.COV2.S vaccine. The results showed that booster vaccinations increased the levels of S-specific binding antibodies, neutralizing antibodies, and T-cell responses compared to a single Ad26.COV2.S vaccination. Boosters containing mRNA-based vaccines induced significantly higher levels of binding antibodies than homologous boosters. The mRNA-1273 booster was the most immunogenic but had higher reactogenicity compared to the BNT162b2 and Ad26.COV2.S boosters. Local and systemic reactions were generally mild to moderate in the first 2 days after booster administration.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Medicine, General & Internal
R. L. Atmar et al.
Summary: This study investigated the efficacy of homologous and heterologous booster vaccines in adults who had completed a primary Covid-19 vaccine regimen. The results showed that both types of booster vaccines were safe and immunogenic.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Immunology
Helen Parry et al.
Summary: Delaying the second dose of the BNT162b2 vaccine can significantly boost antibody response in older people, providing a longer period of protection and delaying the need for booster vaccination. However, in terms of cellular-specific response, the best results were achieved with the standard vaccine interval.
Article
Medicine, Research & Experimental
Thuy Trang Nguyen et al.
Summary: This study assessed the reactogenicity and immunogenicity of heterologous COVID-19 vaccination regimens and found that these regimens showed higher immunogenicity and tolerable reactogenicity. Additionally, they provided potential protection against the variant of concern, including the Delta variant.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Review
Medicine, General & Internal
Baoqi Zeng et al.
Summary: This study conducted a systematic review and meta-analysis to assess the effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern (VOC). The results showed that full vaccination was highly effective against the Alpha variant and moderately effective against the Beta, Gamma, and Delta variants. Booster vaccination was more effective against the Delta and Omicron variants. mRNA vaccines appeared to have higher effectiveness against the VOC compared to other vaccines.
Article
Biochemistry & Molecular Biology
Abishek Chandrashekar et al.
Summary: This study demonstrates that the mRNA-based BNT162b2 vaccine and the adenovirus-vector-based Ad26.COV2.S vaccine provide robust protection against the SARS-CoV-2 Omicron variant. However, some vaccinated animals with moderate immune responses failed to fully control the virus.
Editorial Material
Infectious Diseases
Edward P. K. Parker et al.
LANCET INFECTIOUS DISEASES
(2022)
Article
Immunology
Sira Nanthapisal et al.
Summary: This study evaluated the immunogenicity and reactogenicity of a standard- versus low-dose ChAdOx1 nCoV-19 vaccine booster after CoronaVac in healthy adults. The results showed that the low-dose booster had noninferior immunogenicity and lower systemic reactogenicity compared to the standard-dose booster. Therefore, the use of a fractional low-dose booster may be considered, especially in resource-constrained settings.
Article
Multidisciplinary Sciences
Fanglei Zuo et al.
Summary: This study demonstrates that an mRNA vaccine booster in individuals vaccinated with inactivated vaccines can significantly increase the humoral and cellular immune responses against the virus, including the Omicron variant.
NATURE COMMUNICATIONS
(2022)
Article
Medicine, General & Internal
Wing Ying Au et al.
Summary: The study evaluates the effectiveness of heterologous and homologous COVID-19 vaccine regimens in preventing COVID-19 infections, hospital admissions, and death. Results show that a three-dose mRNA vaccine regimen is most effective against asymptomatic and symptomatic COVID-19 infections, while a homologous two-dose mRNA regimen is highly effective in preventing severe COVID-19 infections.
BMJ-BRITISH MEDICAL JOURNAL
(2022)
Review
Infectious Diseases
Jingjing Lv et al.
Summary: Heterologous prime-boost vaccination with ChAd and BNT (mRNA-1273) vaccines can achieve comparable immunogenicity and even better outcomes compared to homologous vaccination with BNT/BNT. However, it is associated with an increased risk of local and systemic reactions.
INFECTIOUS DISEASES OF POVERTY
(2022)
Article
Medicine, General & Internal
Cecile Janssen et al.
Summary: The study aimed to compare the immune response induced by heterologous and homologous SARS-CoV-2 mRNA vaccinations. Results showed higher levels of neutralizing antibodies with heterologous vaccination, but also more severe adverse reactions.
Article
Medicine, General & Internal
Alasdair P S Munro et al.
Article
Medicine, General & Internal
Sara Y. Tartof et al.
Summary: This study aimed to assess the overall and variant-specific effectiveness of the BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19-related hospital admissions among members of a healthcare system in California. The effectiveness of the vaccine remained high against hospital admissions even up to 6 months after full vaccination, despite a decline in effectiveness against SARS-CoV-2 infections over time, which was likely due to waning immunity rather than the delta variant escaping vaccine protection.
News Item
Multidisciplinary Sciences
Smriti Mallapaty
Article
Biochemistry & Molecular Biology
Koen B. Pouwels et al.
Summary: A large, community-based study in the United Kingdom indicates that the effectiveness of BNT162b2 and ChAdOx1 vaccines against SARS-CoV-2 infections with symptoms or high viral burden is reduced with the Delta variant compared to the Alpha variant. Although the effectiveness of two doses is at least as great as protection afforded by prior natural infection, there are significant differences in the dynamics of immunity after the second dose between BNT162b2 and ChAdOx1.
Letter
Medicine, General & Internal
Ai-ris Y. Collier et al.
Summary: The kinetics of immune response to Covid-19 vaccines were studied, showing varying peak levels and durations of response for different vaccines. However, the response levels correlating with protection have not been defined yet.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Hiam Chemaitelly et al.
Summary: In a study conducted in Qatar involving over 900,000 participants, vaccine effectiveness peaked at 77.5% in the first month after the second dose. However, it declined afterwards to as low as 20% in months 5 through 7 after vaccination, while protection against severe Covid-19 remained above 90% for at least 6 months.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Merryn Voysey et al.
Summary: The AZD1222 vaccine has been approved for emergency use in the UK with an interval of 4-12 weeks between doses. Analysis shows that the vaccine is efficacious with two doses and provides immunoprotection after the first dose before the second dose is administered.
News Item
Medicine, General & Internal
Marta Paterlini
BMJ-BRITISH MEDICAL JOURNAL
(2021)
Article
Immunology
Porntip Intapiboon et al.
Summary: The study found that after receiving an intradermal booster of the BNT162b2 mRNA vaccine, systemic side effects were significantly reduced, providing a good level of antibody response, making it a suitable alternative strategy in vaccine management.
Article
Medicine, General & Internal
Robert H Shaw et al.
News Item
Multidisciplinary Sciences
T. V. Padma
Summary: The surge of coronavirus cases in India poses a risk to global vaccine supplies.
Article
Medicine, General & Internal
Andreas Greinacher et al.
Summary: After vaccination with ChAdOx1 nCov-19, rare immune thrombotic thrombocytopenia can occur due to platelet-activating antibodies against PF4, resulting in various thrombotic events. Most patients in this case series were women, with fatal outcomes such as cerebral venous thrombosis and intracranial hemorrhage. Additional studies are needed to further investigate and understand this phenomenon.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Review
Medicine, General & Internal
Matthew J. Page et al.
Summary: The PRISMA statement was designed to help systematic reviewers transparently report the purpose, methods, and findings of their reviews. The updated PRISMA 2020 statement includes new reporting guidance, a 27-item checklist, an abstract checklist, and revised flow diagrams for reviews.
BMJ-BRITISH MEDICAL JOURNAL
(2021)
Review
Immunology
Nan-Chang Chiu et al.
Summary: The study showed that heterologous administration of a BNT162b2 boost in ChAdOx1-primed participants demonstrated robust immunogenicity and tolerable reactogenicity, along with stronger T cell responses. It suggests that heterologous vaccination is a viable strategy to combat COVID-19, but further research is needed to confirm its benefits and determine the optimal combinations, doses, and intervals.
EXPERT REVIEW OF VACCINES
(2021)
Article
Medicine, General & Internal
Xinxue Liu et al.
Summary: Heterologous prime-boost COVID-19 vaccine schedules could facilitate mass immunisation, with ChAd/BNT showing non-inferior immunogenicity compared to ChAd/ChAd, but BNT/ChAd did not demonstrate non-inferiority to BNT/BNT. The results support flexibility in using heterologous prime-boost vaccination with ChAd and BNT COVID-19 vaccines.
Article
Medicine, General & Internal
Alberto M. Borobia et al.
Summary: To date, there are no immunological data on COVID-19 heterologous vaccination schedules in humans. This study evaluated the immunogenicity and reactogenicity of administering BNT162b2 as a second dose in individuals primed with ChAdOx1-S. The results showed that BNT162b2 induced a robust immune response in individuals prime vaccinated with ChAdOx1-S, with an acceptable and manageable reactogenicity profile.
News Item
Multidisciplinary Sciences
T. V. Padma
Article
Biochemistry & Molecular Biology
Tina Schmidt et al.
Summary: In healthy adults, vaccination with an mRNA vaccine as a booster, regardless of the initial vaccine, resulted in higher levels of spike-specific antibodies and T cells compared to booster vaccination with ChAdOx1 nCov-19. Heterologous vaccination with ChAdOx1 nCoV-19 followed by an mRNA vaccine induced strong immune responses with acceptable reactogenicity, showing similar or better effects than homologous mRNA vaccine regimens.
Article
Biochemistry & Molecular Biology
Joana Barros-Martins et al.
Summary: A study found that booster vaccination with BNT162b2 in healthcare professionals previously vaccinated with ChAdOx-1 nCoV-19 elicited more neutralizing antibodies and higher frequencies of virus-specific T cells. Additionally, BNT162b2 induced high titers of neutralizing antibodies against variants of concern, such as B.1.1.7, B.1.351, and P.1.
Letter
Medicine, General & Internal
Johan Normark et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Multidisciplinary Sciences
Xingyu Li et al.
Summary: The COVID-19 pandemic has severely disrupted global health and supply chains, highlighting the critical need for timely production of key resources to combat outbreaks. Strategies to balance pandemic control and economic losses are crucial, emphasizing the importance of cross-sectoral coordination and regional collaboration in containing and preparing for future pandemics.
SCIENTIFIC REPORTS
(2021)
Article
Critical Care Medicine
David Hillus et al.
Summary: This study evaluated the reactogenicity and immunogenicity of homologous and heterologous COVID-19 vaccinations, with results showing that heterologous immunization has good immunogenicity and tolerability.
LANCET RESPIRATORY MEDICINE
(2021)
Article
Immunology
Louise Benning et al.
Summary: This study demonstrates that heterologous ChAdOx1 nCoV-19/BNT162b2 vaccination is safe and induces a strong and broad humoral response in healthy individuals.
Review
Immunology
Yu-Jing Fan et al.
Summary: This systematic review and meta-analysis compared the safety and efficacy of COVID-19 vaccines, finding that mRNA vaccines were more associated with serious adverse events, while two doses of mRNA vaccines were most effective in reducing the risk of SARS-COV-2 infection. All vaccines were effective in reducing the risk of severe infection.
Article
Multidisciplinary Sciences
Petra Mlcochova et al.
Summary: The B.1.617.2 (Delta) variant of SARS-CoV-2 has lower sensitivity to antibodies and higher replication efficiency compared to other lineages, which may contribute to its dominance and reduced vaccine effectiveness, highlighting the need for continued infection control measures post-vaccination.
Article
Health Care Sciences & Services
Dehui Luo et al.
STATISTICAL METHODS IN MEDICAL RESEARCH
(2018)
Article
Health Care Sciences & Services
Areti Angeliki Veroniki et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY
(2016)
Article
Multidisciplinary Sciences
Georgia Salanti et al.
Review
Immunology
Federica Sallusto et al.
